IQ-AI Limited Keck Medical Centre of USC Purchases IB's Software (0876Z)

TIDMIQAI

RNS Number : 0876Z

IQ-AI Limited

16 September 2020

IQ-AI Ltd

("IQ-AI" or the "Company")

Keck Medical Center of USC Purchases Imaging Biometrics' Software

Imaging Biometrics(R), LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), is pleased to announce that the Keck Medical Center of USC has purchased IB Clinic for automatically generating IB's quantitative parameter maps. The installation provides Keck Medical Center with a processing solution that allows for standardised brain tumour imaging across multiple sites and platforms for its patients.

IB clinic includes the IB Neuro(TM) module, which generates images of relative cerebral blood volume (rCBV), a magnetic resonance imaging (MRI) method for evaluating brain tumours. As many studies have shown, higher rCBV is correlated with more aggressive tumours (higher tumour grade) and provides information for diagnosis and treatment optimisation. IB Neuro's capabilities from its inception are consistent with national consensus recommendations for collecting and processing rCBV data as published in Neuro-Oncology.

Unique to IB Neuro is the ability to automatically account for variability inherent with MRI systems by translating the relative MR intensity values to a fixed and consistent scale regardless of scanner platform, field strength, patient, or time point. Quantitatively assessing how a tumour is changing over time is critical for both clinicians and their patients.

"The reliability of IB Neuro's rCBV maps empower our physicians with confidence that we are making the right decisions for our patients," says Mark Shiroishi, MD, Director of Neuro-Oncology Imaging at Keck Medical Center and Chief of Pediatric Neuroradiology at the LA County/USC Medical Center.

IB Clinic's imaging suite at Keck Medical Center includes automated Delta T1(TM) maps, quantitative subtraction maps proven to eliminate confounding artifacts, such as blood products, and enable objective and rapid identification of true contrast enhancing regions for radiologists. The two biomarkers, IB's Delta T1 and rCBV maps, provide complementary information that aids the diagnostic process and improves productivity.

"We are excited that Keck Medical Center has adopted our brain tumour imaging platform. IB Clinic's quantitative output is ideal for major cancer centers such as Keck Medical Center as it automates and standardises care across sites, scanners, and patients. We are equally excited for the collaborative research relationships now established between our two organisations and translating future developments that may result," said Michael Schmainda, CEO of IB.

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

 
 IQ-AI Limited 
  Trevor Brown/Vinod Kaushal/Qu Li 
  Tel: [phone] 
---------------------------------------------------------- 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Heena Karani 
  Tel: [phone] 
---------------------------------------------------------- 
 

About Keck Medicine of USC

Keck Medicine of USC is the University of Southern California's medical enterprise, one of only two university-based medical systems in the Los Angeles area. Keck Medicine combines academic excellence, world-class research and state-of-the-art facilities to provide highly specialized care for some of the most acute patients in the country.

Its internationally renowned physicians and scientists provide world-class patient care at Keck Hospital of USC, USC Norris Cancer Hospital, USC Verdugo Hills Hospital and more than 80 outpatient locations in Los Angeles, Orange, Kern, Tulare and Ventura counties.

Keck Medical Center of USC was ranked among the top 20 hospitals nationwide on U.S. News & World Report's 2020-21 Best Hospitals Honor Roll and among the top 3 hospitals in Los Angeles and top 5 in California.

About Imaging Biometrics, LLC

Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STRSFAFMIESSESU

(END) Dow Jones Newswires

September 16, 2020 02:00 ET (06:00 GMT)